A new study is raising the possibility that GLP-1 medications could do more than help with weight loss and blood sugar control - they may also influence how the body ages. Researchers found that older female mice treated with semaglutide, the drug behind Ozempic and Wegovy, lived a median of 834 days compared with 742 days for untreated mice - about 12% longer. The treated mice also showed better physical function and fewer biological signs linked to aging, including inflammation and cellular decline. The findings are promising, but researchers stress that the evidence is still limited to animals, and long-term studies will be needed to determine whether GLP-1 drugs can extend healthy lifespan in humans. #ozempic #wegovy #weightloss #study #science